"Promising Strategies Show Early Success in Treating Aggressive Brain Tumors"

A new strategy to combat aggressive brain cancer involves using patients' own immune cells to create "living drugs" that can target and attack glioblastoma. In early tests, this approach showed promise in shrinking tumors, with some patients experiencing temporary tumor reduction. Two separate teams at Massachusetts General Hospital and the University of Pennsylvania developed next-generation CAR-T versions to overcome glioblastoma's defenses. While the results are encouraging, researchers emphasize the need to make the treatment longer-lasting.